RET proto-oncogene encodes a receptor tyrosine kinase whose ligand is glial cell line-derived neurotrophic factor (GDNF), and its polymorphism at G691S juxtamembrane region (RETp) is a germline polymorphism. Cutaneous melanomas, particularly the desmoplastic subtype, are highly neurotropic; thus we sought to determine the frequency of RETp in cutaneous melanoma and its functional responsiveness to GDNF. RETp was assessed in 71 non-desmoplastic cutaneous melanomas (non-DMs) and 70 desmoplastic melanomas (DMs). Melanoma cell lines with RETp, RET wild type (RETwt), BRAF V600E mutation (BRAFmt) or BRAF wild type (BRAFwt) were assessed for functional activity. RETp frequency was significantly higher in DMs (61%) than in non-DMs (31%, Po0.001). BRAFmt was detected in only 11% of DMs. GDNF stimulation significantly amplified cell proliferation, migration and invasion in RETp, but not in RETwt melanoma cells. GDNF stimulation of RETp cell lines enhanced phosphorylation of extracellular signalregulated kinase (ERK) and Akt of the RET-RAS-RAF-ERK and RET-phosphatidylinositol 3-kinase (PI3K)-Akt pathways, respectively. GDNF response of RETp cells in signal transduction and other functional studies were not affected by BRAFmt. The study demonstrates that RETp is frequently found in cutaneous melanoma, particularly desmoplastic subtypes, and responds to GDNF inducing events favorable for tumor progression.
Introduction
Melanoma is of neuroectodermal origin and has a high propensity to invade and metastasize to neural-origin tissue, such as the central nervous system and brain, which often contributes to the poor prognosis (Hoon et al., 2001) . Desmoplastic melanoma (DM) is a subtype of cutaneous melanoma with distinct clinicopathologic characteristics that distinguish it from other cutaneous melanomas (Jaroszewski et al., 2001) . DMs often arise in highly sun-exposed areas, especially the head and neck region, and have a greater propensity to invade nerves and have aggressive local growth (Quinn et al., 1998; Livestro et al., 2005) . Reports have shown more frequent local recurrence of DMs compared to nondesmoplastic cutaneous melanomas (non-DMs; Busam, 2005) , but there are no reported studies on the potential mechanisms involved in the neurotropism of DMs or non-DMs.
RET is a proto-oncogene that encodes a receptor tyrosine kinase (RTK; Takahashi et al., 1988 Takahashi et al., , 1989 Iwamoto et al., 1993; Zbuk and Eng, 2007) containing four cadherin-related motifs and a cysteine-rich region in the extracellular domain (Iwamoto et al., 1993; Takahashi, 2001) . Glial cell line-derived neurotrophic factor (GDNF), a major ligand of RET, is a growth factor that facilitates the survival of dopaminergic neurons of the midbrain (Lin et al., 1993; Airaksinen and Saarma, 2002) . GDNF binds to the extracellular domain of RET through the formation of a complex with glycosyl-phosphatidylinositol-anchored coreceptor (GFRa1-3), a member of the GDNF receptor family that can bind to GDNF and RET (Takahashi, 2001) . Although the expression of GFRa3 is higher in DMs than non-DMs , it has not been linked to the neurotropism of DMs.
Activation of RET induces signaling through the RAS-BRAF-ERK, phosphatidylinositol 3-kinase (PI3K)-Akt and p38 mitogen-activated protein kinase (MAPK) pathways that initiate various functions in cells (Takahashi, 2001) . Activation of both the RET-RAS-BRAF-MEK-ERK and RET-PI3K-Akt pathways has been implicated in cell proliferation and survival, whereas the RET-PI3K pathway has been associated more frequently to cell motility (Takahashi, 2001; Kodama et al., 2005) . All cancer-related mutations of the RET gene in the cysteine-rich region or tyrosine kinase domain (intracellular domain) are ligand-independent and reportedly responsible for development of multiple endocrine neoplasia 2A and 2B, familial medullary thyroid carcinoma and papillary thyroid carcinoma (Kondo et al., 2006; Runeberg-Roos and Saarma, 2007; Weber and Eng, 2008) . G691S RET polymorphism (RETp) is a single nucleotide polymorphism alteration in exon 11 of the juxtamembrane region of RET that enhances the response of RET to GDNF as previously shown by our group in pancreatic cancer (Sawai et al., 2005) ; the RET G691S responsiveness to GDNF was assessed in pancreas cancer because of its known neurotropism. As cutaneous melanomas, particularly DM, are highly neurotropic, we hypothesized that RETp may play a role in enhancing this functional behavior. In this study, the objective was to investigate the frequency and functional activity of RETp in cutaneous melanoma.
Somatic BRAF mutations are well documented and are frequently found in non-DMs (Davies et al., 2002) . The most frequent BRAF mutation is a single substitution in exon 15, V600E, which is a constitutive active form (Davies et al., 2002; Shinozaki et al., 2004) . BRAF belongs to the RAF family of serine-threonine kinases and is a component of the RET-RAS-BRAF-MAPK kinase (MEK)-ERK signaling pathway (Melillo et al., 2005) . This signaling pathway is a membrane-to-nucleus signaling system controlling cell proliferation and other functions in mammalian cells (Dhomen and Marais, 2007) . Although V600E BRAF mutation (BRAFmt) is suggested to cause abnormal proliferation of melanoma cells (Sumimoto et al., 2004) , its relationship to RETp in cutaneous melanoma is not known.
In this study, the frequency of RETp in DMs and non-DMs was assessed. We found that RETp is frequently present in cutaneous melanomas, and more frequent in neural tissue invading DMs. RETp was shown to be highly responsive to the ligand GDNF inducing various physiological activities. This is the first report describing the detection and functional activity of RETp in cutaneous melanomas.
Results

Expression of RET, GFRa1 and GFRa3
To confirm the existence of GDNF-RET signaling pathway in melanoma, the mRNA expressions of RET, GFRa1 and GFRa3 were analysed in melanoma lines using quantitative real-time PCR (qRT). All melanoma lines expressed mRNA of RET, GFRa1 and GFRa3 (Figure 1a ). The patterns of mRNA expression were independent of RETp presence (RETp status of cells shown below). Normal human brain tissues (B36929, B37876) served as positive controls for GFRa1 and GFRa3 mRNA, and human normal melanocytes (HMC) were used as a control. Immunohistochemistry (IHC) was performed to confirm the expression of the RET in melanoma tissues. IHC analysis of both nonDMs and DMs demonstrated that RET was expressed independently of RETp status in melanoma tissue ( Figure 1B ). There were no significant increase in RET protein expression in RET wild type (RETwt) versus RETp melanomas. RET expression in melanoma cell lines was shown by western blot analysis ( Figure 1C ).
Analyses of RETp and BRAFmt
As BRAF is downstream of the signaling pathway of RET, and BRAFmt may influence the signaling activation of RET (Takahashi, 2001; Davies et al., 2002) , we investigated RETp (RET G691S polymorphism), BRAFmt (BRAF V600E mutation), RETwt and BRAF wild type (BRAFwt) in melanoma lines. Melanoma lines were assayed for both RETp (G691S) and BRAFmt (V600E): ME1 was RETp and BRAFmt; ME5 and ME7 were RETp and BRAFwt; ME3 and ME10 were RETwt and BRAFwt; M16 was RETwt and BRAFmt. For RETp detection, the results were also validated using direct sequencing. The sequence of RETwt had a single polymorphic nucleotide change (GGT-AGT) to RETp (Supplementary Figure 1S) .
RETp and BRAFmt DNA analyses were performed on histopathologically verified surgical tissues of nonDMs (n ¼ 71) and DMs (n ¼ 70). The frequency of RETp was about twice as high in DMs (61%) as compared to non-DMs (31%; Po0.001; Table 1;  Supplementary Table 2S) . BRAFmt was significantly (Po0.001) higher in non-DM (39%) than DM tumors (11%). The reduced frequency of BRAFmt in DMs was striking and has important implications as to the role of BRAFmt in highly sun-exposed sites of cutaneous melanomas overall. Details of RETp and BRAFmt analysis of primary and metastatic tumors were assessed (Table 1; Supplementary Table 2S) . BRAFmt was detected more frequently in metastatic than in primary tumors in both non-DMs and DMs. However, this was not the case in RETp for non-DMs and DMs.
Effect on GDNF-induced proliferation
The effects of RETp and BRAFmt on GDNF-induced cell proliferation were analysed. A 48-h exposure to GDNF enhanced proliferation of RETp melanoma cells but not of RETwt melanoma cells (Figure 2a ). GDNF did not differentially enhance the proliferation of BRAFmt and BRAFwt cells (Figure 2a ). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay results were confirmed by a direct cellcounting assay performed 72 h after administration of GDNF (Figure 2b ). We selected 25 ng/ml of GDNF as the optimal working dose for assessing cell proliferation (Figure 2a) .
The pathway for GDNF-induced proliferation was confirmed by using agents that block components of the two important pathways for RET signaling. PD98059 is a MEK1 inhibitor that targets the RET-RAS-BRAF-MEK-ERK pathway. Wortmannin is a PI3K inhibitor that targets RET-PI3K-Akt pathway. PD98059 treatment completely suppressed GDNF-induced proliferation. Wortmannin partially suppressed GDNF-induced proliferation in ME7 (RETp/BRAFwt; Figure 2c ). This suggested that the RET-RAS-BRAF-MEK-ERK signaling pathway plays a more predominant role than the RET-PI3K-Akt pathway with respect to GDNF-in- Functional RET G691S polymorphism in cutaneous melanoma N Narita et al duced cell proliferation in RETp melanoma cells. To exclude the possibility that crosstalk signaling pathways via other receptors are involved in GDNF activation of RET signaling pathways, we transfected small interfering RNA (siRNA) against RET in RETp cells (ME1), and GDNF-induced cell proliferation was assessed. The RET siRNA significantly (Po0.05) reduced expression of RET mRNA 24 and 48 h after transfection by 77 and 76%, respectively, compared to the vehicle-treated cells (control; Figure 2d ). The nonspecific siRNA control did not significantly affect mRNA expression of RET ( Figure 2d ). RET siRNA significantly (Po0.05) suppressed >80% of cell proliferation induced by GDNF (25 ng/ml) 48 h after stimulation, whereas nonspecific control siRNA did not ( Figure 2e ). These results suggest that crosstalk signaling through other receptors is not involved in the RET pathways activated by GDNF.
GDNF effect on RETp cell migration and invasion Next, to assess whether RETp affects cell migration or invasion induced by GDNF via the RET-PI3K pathway, migration and invasion assays were performed using microporous-membrane and collagen-coated chambers, respectively. RETp cells showed more vigorous migration and invasion than RETwt cells after GDNF stimulation (Figures 3a and b ). BRAFmt cells demonstrated no difference on cell migration and invasion after GDNF treatment (Figures 3a and b) . Wortmannin significantly suppressed cell migration induced by GDNF in ME5 (RETp/BRAFwt; Figure 3c ), whereas PD98059 did not ( Figure 3d ). These results suggest that the RET-PI3K signaling pathway plays an important role in cell motility induced by GDNF in RETp melanoma cells. The invasion ability of ME1 (RETp/BRAFmt) enhanced by GDNF was significantly suppressed with RET-specific antibody (Ab; Figure 3e ). Nonspecific purified anti-goat immunoglobulin-G (IgG) was used as a control and did not show any effects (Figure 3e ). These results confirmed that crosstalk signaling pathways via other receptors are not significantly involved in GDNF activation of RET signaling pathways.
Phosphorylation of ERK1/2 and Akt by GDNF
To assess the effect of RETp activation on downstream factors of the RET signaling pathway, we analysed whether RETp or BRAFmt enhanced phosphorylation of ERK1/2 and Akt using western blotting because RET-RAS-BRAF-MEK-ERK and RET-PI3K-Akt are the major signaling pathways activated by GDNF stimulation leading to cell proliferation (Takahashi, 2001) . In a representative cell line, ME3 (RETwt/ BRAFwt), GDNF showed weak phosphorylation of ERK1/2 and Akt. In contrast, GDNF strongly phosphorylated ERK1/2 and Akt within 15 min after treatment in ME1 (RETp/BRAFmt), ME7 and ME5 (RETp/BRAFwt); and the phosphorylation of ERK1/2 and Akt lasted for 60 min (Figures 4a-d ). These results confirm that RETp enhanced the response of both RET-RAS-BRAF-MEK-ERK and RET-PI3K-Akt signaling pathways after GDNF stimulation.
Actin polymerization in melanoma cells by GDNF Morphological alterations occurred during migration of melanoma cells after GDNF treatment. Actin polymerization on the cell surface was observed to confirm cell motility induced by GDNF in RETp cells. Based on the migration assays, we selected 10 ng/ml of GDNF for assessment of cell motility. Actin polymerization, such as filopodia, necessary for cell migration, was visualized using Alexa Fluor 568 phalloidin staining. Administration of GDNF induced filopodia in RETp cell lines (ME1, ME7), but not in the RETwt cell line (ME3; Supplementary Figure 2S ). The findings support the cell migration/invasion assays.
Discussion
RET gene expression has been detected primarily in human tumors of neural crest origin, such as neuroblastoma, pheochromocytoma and medullary thyroid carcinoma (Takahashi, 2001) . RETp was originally found in radiation-induced thyroid tumors and sporadic medullary thyroid cancers (Bounacer et al., 2002; Elisei et al., 2004) . In this report, we identified high frequency of RETp in cutaneous melanomas, particularly and more frequently in DMs (non-DMs: 31%, DMs: 61%), whereas RETp has been detected in only 15-20% of the normal population (Ceccherini et al., 1994; Bounacer et al., 2002; Elisei et al., 2004; Stephens et al., 2005) . As not all DMs are neurotropic, we did not find RETp in all DMs. Previously, it was demonstrated that the G691S RETp was present in pancreas and thyroid cancers (Elisei et al., 2004; Sawai et al., 2005) . Only certain RET-expressing tissues, such as the thyroid gland, have been shown to have RET gene rearrangements that lead to physiological changes (Airaksinen and Saarma, 2002; Runeberg-Roos and Saarma, 2007) . This is the first report demonstrating GDNF's significant effects in promoting proliferation, migration and invasion of RETp versus RETwt melanoma cells. These findings suggest that RETp melanoma may be more aggressive when in the vicinity of GDNF releasing neural and other tissues. Peripheral neural tissues secrete GDNF and are invaded by cutaneous melanomas. Brain Functional RET G691S polymorphism in cutaneous melanoma N Narita et al metastasis is one of the major causes of death for melanoma patients (Selek et al., 2004) ; GDNF secreted by glial cells in the brain could significantly contribute to proliferation and migration of RETp melanoma cells. The observation that RETp is more frequent in DMs and responsive to the neurotrophic factor GDNF in non-DMs suggests that this RTK may play a significant role in melanoma progression.
RETp-GDNF enhanced and prolonged the phosphorylation of the ERK and Akt. PD98059, an MEK1 inhibitor, significantly blocked the cell proliferation induced by GDNF, whereas wortmannin, a PI3K inhibitor, only suppressed GDNF-enhanced proliferation of RETp cells to some extent. These results suggested that both pathways of RET-RAS-BRAF-MEK-ERK and RET-PI3K-Akt (Kodama et al., 2005) can be activated Non-specific control siRNA +GDNF 25ng/ml GDNF 25ng/ml GDNF (-) RET siRNA + GDNF 25ng/ml ** Figure 2 Cell proliferation by glial cell line-derived neurotrophic factor (GDNF). (a) Proliferation of melanoma cells was analysed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were treated with 5 ng/ml, 25 ng/ml or 50 ng/ml of GDNF in serum-free medium for 48 h. Copy numbers of RET mRNA were normalized using mRNA copy numbers of the housekeeping gene, GAPDH, and expressed as relative copies. (e) GDNF (25 ng/ml) was administrated to ME1 48 h after transfection of RET specific siRNA or nonspecific siRNA. Bars±s.d. show increase (fold) compared to delivery agent-treated control (without GDNF). * , **Po0.05.
Functional RET G691S polymorphism in cutaneous melanoma N Narita et al through RETp-GDNF induction and are inline with the results of proliferation assays, in which GDNF only enhanced cell proliferation in RETp cells. The results of migration and invasion assays showed that RET-PI3K pathway played a significant role in GDNF-induced cell motility. A recent report has shown that Akt-induced phosphorylation plays an integral role in the vertical growth of melanoma (Govindarajan et al., 2007) . It is possible that GDNF-induced cell motility is the result of activation of both RET-PI3K-RAC and RET-PI3K-Akt pathways. The assessment of the RET-RAS-BRAF-MEK-ERK pathway becomes complicated as it is known Functional RET G691S polymorphism in cutaneous melanoma N Narita et al that signal transduction through the BRAFmt (V600E), a member of this pathway, is quite frequent in melanomas; signal transduction through NRAS mutation occurs to a much lesser extent (Curtin et al., 2006) . We demonstrated that GDNF stimulation of RETp cells was not significantly influenced by BRAFmt presence. 
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We demonstrated that BRAFmt in melanoma cells does not significantly affect GDNF-induced proliferation, migration and invasion. Although BRAFmt phosphorylates downstream factors such as MEK or ERK without ligand stimulation (Davies et al., 2002; Satyamoorthy et al., 2003) , GDNF induces more intense phosphorylation of ERK1/2 in RETp/BRAFmt cells (ME1). This suggests that BRAFmt only partially phosphorylates the ERK pathway and its downstream factors, and consequently, cells bearing BRAFmt may not exhibit further ERK phosphorylation after GDNF stimulation, which is compatible with our results. These data also confirm our previous finding that BRAFmt is more frequent in metastasis than primary melanomas (Shinozaki et al., 2004) . Our studies suggest that BRAFmt is not a significant progression factor for all types of cutaneous melanomas. Linkage of sun exposure to BRAFmt frequency may not be valid for all cutaneous melanomas, because DMs are known to be more frequently found in highly sun-exposed areas (Quinn et al., 1998) . DMs had a significantly lower level (>3-fold) of BRAFmt compared to non-DMs. This finding supports a previous report on BRAFmt in DMs in a small cohort of patients (Davison et al., 2005) .
There are several new therapeutic agents of RTK inhibitors affecting RET in clinical trials. Sorafenib (BAY 43-9006, serine/threonine kinase RAF1 and BRAF inhibitor) and semaxanib (SU5416, vascular endothelial cell growth factor receptor inhibitor) are RTK inhibitors that can block RET signaling and suppress growth of RETp thyroid cancers (Carlomagno et al., 2006; Mologni et al., 2006) . Sorafenib directly suppresses the kinase activity of RET, and promotes lysosomal degradation of RET protein (Plaza-Menacho et al., 2007) . RETp melanomas may be appropriate targets for using these RTK inhibitors, particularly those showing neurotropism. Our findings of melanoma cells with RETp/wt and BRAFmt/wt in combination suggest that some of the current clinical trials with these inhibitors may be working through the RETp pathway. To date, the association of BRAFmt in melanoma with response to sorafenib alone has not been demonstrated.
RETp could be a key factor in the proliferation and invasion of malignant melanoma cells, and its high incidence in DM may explain why this malignancy often exhibits neurotropism. In our study, inhibition of RET signaling suppressed all proliferation and invasion in melanomas. This suggests that RETp could be a new RTK target for treatment of malignant melanomas. Regimens based on RTK inhibitors selective for RET may be particularly promising when, unfortunately, metastatic melanoma therapeutic treatments beyond surgery have had limited success to date.
Materials and methods
Cell lines
All 11 melanoma lines (ME1, ME2, ME3, ME5, ME7, ME8, ME10, ME13, ME20, M16 and M20) used in this study were established and characterized at the John Wayne Cancer Institute and cultured as described previously (Shinozaki et al., 2007; Goto et al., 2008) . Six cell lines (ME1, ME3, ME5, ME7, ME10 and M16) were selected for functional assays based on the presence of RETp, RETwt, BRAFmt and BRAFwt. MIAPaCa-2, PANC-1 (human pancreatic cancer) and MCF-7 (human breast cancer) were obtained from American Type Culture Collection (Manassas, VA, USA). HMC and normal brain tissues (B36929, B37876) were purchased from Cascade Biologics Inc. (Portland, OR, USA) and Cooperative Human Tissue Network (Nashville, TN, USA), respectively.
Tissue specimens
Formalin-fixed, paraffin-embedded tumor tissues were obtained from non-DM (n ¼ 71) and DM patients (n ¼ 70). All patients had undergone surgical treatment for primary or metastatic melanoma at Saint John's Health Center or Sydney Melanoma Unit, and the use of human specimens was approved by the respective institutional review boards.
DNA extraction
For the preparation of melanoma line DNA, cells were lysed in DNAzol Genomic DNA Isolation Reagent (Molecular Research Center, Cincinnati, OH, USA), and DNA precipitated by 100% ethanol was measured by UV spectrophotometry (Fujiwara et al., 1999) . For the preparation of melanoma tissue DNA, 8 mm sections were cut from formalin-fixed, paraffinembedded blocks and mounted on glass slides. Sections were stained with H&E for microscopic analysis to confirm histopathology. Tumor and normal tissues were isolated separately by microdissection under light microscopy, as previously described (Umetani et al., 2005) . Dissected tissues were digested with Proteinase K (Qiagen, Valencia, CA, USA)-containing lysis buffer at 50 1C overnight and inactivated by heat at 75 1C for 15 min. DNA was then purified with phenol-chloroform-isoamyl-alcohol, precipitated by ethanol and quantified by PicoGreen dsDNA Assay Kit (Invitrogen, Carlsbad, CA, USA) for double-stranded DNA (Umetani et al., 2005) .
mRNA expression analysis
The sequence of primers and fluorescence resonance energy transfer (FRET) probes used for the qRT assay of RET, GFRa1, GFRa3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are shown in Supplementary Table 1S . Reverse transcription (RT) reactions were performed with Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI, USA) with oligo (dT) primer. The qRT assay was performed in an iCycler iQ Real-Time Thermocycler Detection System (Bio-Rad Laboratories, Hercules, CA, USA). cDNA (5 ml) generated from 250 ng of total RNA through RT was added to a 96-well plate (Fisher, Pittsburgh, PA, USA) in which 0.5 mM of each primer, 0.3 mM FRET probe, 1 U of AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA, USA) and PCR reagents were added . Amplification of samples consisted of a precycling hold at 95 1C for 9 min, then 45 cycles of denaturation at 95 1C for 1 min, annealing for 1 min (at 55 1C for GAPDH, 58 1C for RET, 63 1C for GFRa1, 58 1C for GFRa3) and extension at 72 1C for 1 min. Specific plasmid controls for each marker were synthesized as described previously (Goto et al., 2006) , and copy number calibration curves was generated using threshold cycles of six serially diluted plasmid templates (10 1 -10 6 ). To quantify the copy number, the threshold cycle (Ct) was interpolated from the calibration curve for each sample and mRNA copy number was calculated using Bio-Rad software. GAPDH was used as a control housekeeping gene and the Functional RET G691S polymorphism in cutaneous melanoma N Narita et al relative mRNA copies were obtained as absolute mRNA copies of each gene/absolute mRNA copies of GAPDH . Each assay was performed at least twice, and mean copy numbers were used for analysis.
RETp and BRAFmt analysis We used a peptide nucleic acid (PNA) clamped PCR method to detect RETp and BRAFmt polymorphism in melanoma lines and paraffin-embedded melanomas as previously described (Sawai et al., 2005; Shinozaki et al., 2007) . Briefly, PCR was performed with the primers, probe, and PNA for clamping shown as RET (no. 1) and BRAF in Supplementary  Table 1S . The PCR assay was performed using iCycler iQ realtime PCR. Genomic DNA (X2.5 ng) was applied to a final volume of 25 ml containing each PCR primer, probe (PNA and LNA in BRAFmt detection), each dNTP, MgCl 2 , PCR buffer and AmpliTaq Gold Polymerase. PCR for RET was subjected to a precycling hold at 95 1C for 12 min, followed by 55 cycles at 94 1C for 1 min, 70 1C for 50 s, 58 1C for 50 s and 72 1C for 1 min. PCR for BRAF was subjected to a precycling hold at 95 1C for 10 min, followed by 45 cycles at 95 1C for 1 min, 72 1C for 50 s, 53 1C for 50 s and 72 1C for 1 min. MIAPaCa-2 and PANC-1 were used as RETp and RETwt controls, respectively (Sawai et al., 2005) . DNA of ME2 and MCF7 were used as BRAFmt and BRAFwt controls, respectively (Shinozaki et al., 2007) .
Sequencing
To confirm the results of the PNA clamp PCR assay, we performed direct sequencing on representative samples, as previously described (Sawai et al., 2005) . RET coding regions were amplified by PCR using genomic DNA of melanoma cells and tumor tissues. The primer pair flanking exon 11 of RET genomic DNA was designed as RET (no. 2; Supplementary Table 1S ). PCR sequencing fragments were applied and read with CEQ 8000XL Genetic Analysis System (Beckman Coulter) and analysed by the CEQ 8000XL Series Genetic Analysis System Software (version 8.0).
RET IHC analysis
Sections (5 mm) were obtained from archived formalin-fixed paraffin-embedded non-DMs and DMs. After deparaffinization, endogenous peroxidase activity was quenched by 0.3% H 2 O 2 and nonspecific binding sites were blocked with 5% bovine serum albumin. Sections were treated with boiling citrate buffer for heat-induced epitope retrieval. Goat antihuman polyclonal RET-specific Ab (R&D Systems, Minneapolis, MN, USA) or nonspecific goat IgG (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), as a control (15 mg/ml in blocking buffer), was added to the sections for immunostaining and incubated at 4 1C for 1 h. Ab binding sites were detected by avidin-biotin peroxidase complex solution (LSAB Kit) and 3,3 0 -diaminobenzidine as a chromogen (Dako, Carpinteria, CA, USA). Counterstaining was performed with hematoxylin and assessed by light microscopy.
Western blotting
Cells were washed twice with ice-cold phosphate-buffered saline (PBS) and dissolved in solubilizing buffer (pH 7.5, 20 mM Tris-HCL, 12.5 mM b-glycerophosphate, 2 mM EGTA, 10 mM NaF, 1 mM benzamide, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 1 mM Na 3 VO 4 and protease inhibitor mix (Roche Diagnostics, Indianapolis, IN, USA)) after treatment with 25 mg human recombinant GDNF (Chemicon International, Billerica, MA, USA). Each aliquot of protein (10 mg) was subjected to western blotting analysis. After electrophoresis on 12.5% polyacrylamide gels, the protein was transblotted to Hybond-P (Amersham Life Sciences Inc., Arlington Heights, IL, USA). The blots were blocked with 5% non-fat dry milk, and then incubated with anti-ERK1/2 rabbit polyclonal Ab or antiphosphorylated ERK1/2 rabbit polyclonal Ab (1:1000, Phosphoplus p44/42 MAP Kinase Thr202/ Tyr204; Cell Signaling Technology, Danvers, MA, USA), and then incubated with an horse radish peroxidase (HRP)-conjugated anti-rabbit IgG Ab (1:2000; Cell Signaling Technology). For western blotting of Akt anti-Akt rabbit polyclonal Ab or antiphosphorylated Akt rabbit polyclonal Ab (1:500, Phosphoplus Akt Ser473; Cell Signaling Technology) and a secondary Ab, HRP-conjugated anti-rabbit IgG Ab (1:1000) were used. Subsequently, the blots were developed with ECL Plus Western blotting Detection system (GE Healthcare Life Sciences, Piscataway, NJ, USA). For western blot of RET protein, lysate was prepared in RIPA buffer (Pierce, Rockford, IL, USA) and electrophoresed on Nu-PAGE 4-12% Bis-Tris gel (Invitrogen). Blot was probed with anti-RET polyclonal Ab (Ret (C-19; Santa Cruz) and visualized using Pierce Supersignal WestFemto chemiluminescence. Loading control was with b-actin.
Cell proliferation assay
Cell proliferation 48 and 72 h after GDNF treatment (5, 25 or 50 ng/ml, dissolved in water) in serum-free medium was analysed by MTT and direct cell counting with a light microscope, respectively. MTT (0.4 mg/ml; Sigma-Aldrich, St Louis, MO, USA) was added into culture wells after washing with PBS. The converted dye was dissolved with dimethyl sulfoxide 2 h after incubation at 37 1C and the absorbance was measured (550 nm) with a microplate reader (Bio-Rad). For cell counting, cells were harvested after washing with PBS and the number of cells was counted using a hemocytometer. In blocking assays, cells were pretreated with 10 mM of a MEK1 inhibitor, PD98059 (Cell Signaling Technology) or 100 nM of a PI3K inhibitor, wortmannin (Cell Signaling Technology), for 60 min before treatment of GDNF as indicated in the manufacturer's instructions, and followed by 25 ng/ml of GDNF treatment for 72 h. To avoid the effect of the delivery agent on cells, PD98059 and wortmannin were dissolved in DMSO, and the same amount of DMSO was added to control (GDNF(À)) and GDNF-treated cells. Each assay was performed at least three times and the mean values were analysed.
Migration assay
Migration ability of the melanoma cells was determined with a modified technique using a Transwell chamber with a microporous membrane (pore size 8 mm; Corning, Corning, NY, USA; Gumireddy et al., 2007) . Melanoma cells were seeded in the upper chamber with RPMI 1640 culture medium (Invitrogen) with 2% fetal bovine serum (FBS). The lower chamber contained RPMI 1640 culture medium with 2% FBS and 5 or 25 ng/ml of GDNF. The cells that migrated through the membrane and adhered to the bottom of lower chamber were fixed with 80% ethanol and stained with hematoxylin 48 h after incubation at 37 1C. The number of stained cells was counted in five fields under a microscope with Â 200 magnification. In blocking assays, cells were pretreated with wortmannin (100 nM) or PD98059 (10 mM) for 60 min before treatment of GDNF as instructions indicated, and followed by treatment with 25 ng/ml GDNF for 48 h. To avoid the effect of the delivery agent on cells, wortmannin or PD98059 was dissolved in DMSO, and the same amount of DMSO was added to control (without GDNF) and GDNF-treated cells.
Each assay was performed at least three times and the mean values were analysed.
Invasion assay
Invasion ability of the melanoma cells was analysed using QCM Collagen-based Invasion Assay (Millipore, Billerica, MA, USA), as described in previous reports (Goto et al., 2006; Gumireddy et al., 2007) . Cells were seeded in the upper chamber with RPMI 1640 culture medium (Invitrogen) with 2% FBS containing GDNF (25 ng/ml). The lower chamber contained RPMI 1640 with 5% FBS and GDNF (25 ng/ml). Cells invading the collagen-coated membrane were fixed and stained 60 h after incubation at 37 1C with reagents. Stained cells were dissolved with a provided reagent and measured at a 550 nm wavelength. In the blocking assay, cells were pretreated with 1 mg/ml of a goat anti-human polyclonal RET-specific Ab, which binds to the extracellular domain of RET (R&D Systems), or 1 mg/ml control goat IgG (Santa Cruz Biotechnology) as a control 60 min before treatment with GDNF and followed by treatment with 25 ng/ml GDNF for 60 h. Each assay was performed at least three times and the mean values were analysed.
RNA interference
An siRNA against RET and a nonspecific control siRNA were designed and synthesized by Dharmacon Inc. (Lafayette, CO, USA). RETp melanoma cells (ME1) were seeded into a 96-well plate (1 Â 10 4 cells/well) without antibiotics. The siRNA was transfected with DharmaFECT-1 Transfection Reagent. The suppression of RET mRNA was confirmed with qRT assay 24 and 48 h after transfection. Each assay using siRNA was performed at least three times and the mean values were analysed.
Actin polymers staining by Alexa Fluor 568 phalloidin Melanoma cells were seeded in BD BioCoat CultureSlides (BD Biosciences, San Jose, CA, USA). Cells were washed twice with PBS and fixed with 3.7% formaldehyde solution for 10 min at room temperature after a 48 h incubation with GDNF (10 ng/ml) at 37 1C. Fixed cells were stained with 1 U/ 200 ml of PBS Alexa Fluor 568 phalloidin (Invitrogen) for 20 min at room temperature. After washing twice with PBS, actin polymers were observed using fluorescence microscopy with Â 400 magnification.
Biostatistical analysis
The correlation of RETp and BRAFmt frequency in DMs and non-DMs was assessed by the w 2 -test. In functional assays, statistical analyses were performed with Wilcoxon's signed ranks test and unpaired t-test. Results are shown as mean þ s.d. A P-value of o0.05 (two-tailed) was considered significant. All statistical analyses were done using JMP software (SAS).
